Last year, the companies filed patent infringement suits against each other, with Boston Scientific alleging infringement by Cordis' CYPHER™ drug-eluting stent and Cordis alleging infringement by Boston Scientific's EXPRESS2™ stent, the platform for its TAXUS™ drug-eluting stent. The June, 2005 trial will involve two of the six patents asserted by Boston Scientific against the CYPHER stent in Delaware and the sole patent asserted by Cordis against the EXPRESS2 stent. A trial for the remaining patents asserted by Boston Scientific will be scheduled at a later date.
On November 21, 2003, the Court denied motions filed by each company seeking preliminary injunctions against the other's drug-eluting stent. Cordis appealed the denial of its motion, and its appeal is scheduled to be heard in April 2004.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, commercialization of new technologies and other factors described in the Company's filings with the Securities and Exchange Commission.